TEMPUS AI INC - CLASS A (TEM)

Lefkofsky said initial demand exceeded ... volume as small and said Tempus has only one month of data following the launch. The company expects hereditary testing growth to reach the mid-teens by year-end. → Carrier Earnings Could Send the Stock to a New All-Time Hi...

Tempus also pointed to 31% year-over-year oncology volume growth and said Data Licensing & Modeling revenue rose 36% year-over-year, but traders are still debating how durable that pace is into the back half. Revenue also topped the Street’s $379.7 million consensus, even as the stock runs into resi…

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data July 31 at 07:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact ...

Tempus AI Inc (TEM) reports strong Q2 2026 results with record revenue, FDA approval for xT CDx, and a major BioNTech partnership, driving a raised outlook for 25% annual growth.